Marina Reacquires Agricultural, Veterinary Rights to RNAi Tech | GenomeWeb

Marina Biotech said this week that it has regained the rights to the use of its transkingdom RNAi technology for agriculture and veterinary applications.

Those rights were previously held by Cambridge Biolabs, formerly ViThera, but the company recently shifted to a new business model, according to Marina. Cambridge Biolabs will retain the rights to the technology for limited veterinary uses, with Marina eligible to receive milestones and royalties.

Additional terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.